Monteris Medical said today it won FDA investigational device exemption clearance for a trial of its NeuroBlate system for treating medically refractory epilepsy. The NeuroBlate system is designed to ablate, necrotize or coagulate soft tissue during neurosurgery procedures through laser thermotherapy, and is not intended for any specific disease or lesion type, the company said. The […]
Monteris Medical said today it is opening a new facility that will act as its headquarters in Plymouth, Minn. on Wednesday this week. Plymouth Mayor Kelli Slavik will host a ribbon cutting event for the new facility, followed by a speech from Monteris CEO John Schellhorn and a tour of the new facility. “As part of […]
Monteris Medical said yesterday that data from a new study of its NeuroBlate minimally invasive robotic laser thermotherapy tool showed improved outcomes for patients undergoing procedures with the device. The findings were presented at the Congress of Neurological Surgeons annual meeting in New Orleans. The NeuroBlate system is an FDA-cleared device designed to ablate, necrotize […]
Second Sight Medical‘s (NSDQ:EYES) newly appointed CEO Will McGuire is set to take the reins starting August 18, the company said. Announced in June, former CEO Dr. Robert Greenberg will become chairman of the board at Second Sight, replacing Alfred Mann who will become chairman emeritus, according to the Sylmar, Calif.-based ‘bionic eye’-developing company. “Will […]
Monteris Medical said a pair of new backers joined a $30 million Series B round it plans to use to expand the commercial footprint of its NeuroBlate robotic brain tumor laser.
OrthoSensor said it added $13 million to its Series B round, taking the total for the round to $48 million as it looks to capitalize on regulatory nods for its Verasense knee replacement device in the U.S. and Europe.
Monteris Medical won a regulatory nod in the U.S. and in Canada for its NeuroBlate MRI-guided tumor ablation device, the company said.
Monteris Medical closed a $7.8 million funding round it plans to use to commercialize its NeuroBlate neurosurgical ablation device for treating brain tumors.
The round, led by Business Development Bank of Canada, also included the SWMF Life Science Fund and several independent parties. Monteris drummed up $9 million last May, according to a press release.